Breaking News Instant updates and real-time market news.

GPRO

GoPro

$15.02

-0.64 (-4.09%)

, FIT

Fitbit

$13.49

-0.41 (-2.95%)

08:45
10/12/16
10/12
08:45
10/12/16
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: GoPro (GPRO) 59.31% +5.41, Fitbit (FIT) 3.45% +0.79, Teva (TEVA) 0.85% +0.60, P&G (PG) 1.39% +0.37, Gold Bear 3x (DUST) 5.45% +0.36, Applied Materials (AMAT) 0.59% +0.34, Genworth Financial (GNW) 0.59% +0.34, Carnival (CCL) 0.59% +0.32, Sprint (S) 0.91% +0.30, and YY (YY) 2.00% +0.29.

GPRO

GoPro

$15.02

-0.64 (-4.09%)

FIT

Fitbit

$13.49

-0.41 (-2.95%)

TEVA

Teva

$44.56

-0.48 (-1.07%)

PG

Procter & Gamble

$88.54

-0.52 (-0.58%)

AMAT

Applied Materials

$28.64

-0.74 (-2.52%)

GNW

Genworth

$5.14

-0.07 (-1.34%)

CCL

Carnival

$46.85

-0.66 (-1.39%)

S

Sprint

$6.78

0.05 (0.74%)

YY

YY

$53.95

-2.33 (-4.14%)

  • 19

    Oct

  • 25

    Oct

  • 25

    Oct

  • 01

    Nov

  • 02

    Nov

  • 06

    Nov

  • 15

    Nov

  • 28

    Nov

  • 08

    Dec

  • 12

    Dec

GPRO GoPro
$15.02

-0.64 (-4.09%)

09/28/16
BOFA
09/28/16
NO CHANGE
BOFA
New drone competitor won't knock down GoPro Karma, says BofA/Merrill
After DJI announced its Mavic drone, BofA/Merrill analyst Jason Mitchell says that the product will appeal more to drone enthusiasts, while GoPro's Karma drone will be more popular with casual consumers and those focused on film. The analyst sees "little risk" to his Q4 estimates for GoPro as a result of Mavic's launch ,since he did not expect GoPro to obtain much revenue from Karma in Q4. Although the analyst believes that Mavic increases GoPro's risk in fiscal 2017, he continues to believe that Karma will be able to obtain a 4%-5% share of the drone market in fiscal 2017. Mitchell keeps a $19 price target and Buy rating on GoPro.
09/28/16
OPCO
09/28/16
NO CHANGE
OPCO
DJI Mavic Pro not a response to GoPro Karma, says Oppenheimer
After drone market leader DJI unveiled its Mavic Pro, Oppenheimer analyst Andrew Uerkwitz notes that he does not see it as a response to GoPro's Karma, arguing that they have two very different value propositions. Mavic is a high-performance, versatile consumer drone that pushes boundaries of the category to new heights, while Karma is a well-rounded and versatile flying camera system, he contended. Nonetheless, Uerkwitz believes GoPro's brand and customer loyalty will be tested given an acceleration in innovation and several compelling drones introduced this year across the market.
09/20/16
09/20/16
NO CHANGE

Stifel still skeptical on new GoPro product line
Stifel analyst Jim Duffy remains skeptical about the ability of GoPro's new Hero5 products to restore enthusiasm in the company's offerings. The analyst says that the company's failure to incorporate "follow me" mode into its new Karma drone and the drone's high price tag are negative. The analyst thinks that Street forecasts of 20% revenue compound annual growth from 2016-2018 "appear aggressive." He keeps a Hold rating on the shares.
09/20/16
OPCO
09/20/16
NO CHANGE
OPCO
Perform
GoPro executing on focused strategy, says Oppenheimer
Oppenheimer analyst Andrew Uerkwitz notes that GoPro has unveiled upgraded cameras, a drone, a hand-held gimbal, and more user-friendly software and services. The analyst believes these upgrades play to GoPro's strengths and will appeal to core users. Further, Uerkwitz says the company keeps executing on a focused strategy that results in what he sees as the "strongest" product portfolio to date. Nonetheless, the analyst points out that concerns over the structural decline of its addressable market keep him on the sideline, reiterating a Perform rating on the shares.
FIT Fitbit
$13.49

-0.41 (-2.95%)

09/29/16
MZHO
09/29/16
NO CHANGE
MZHO
Fitbit Charge 2 checks remain strong, pullback unwarranted, says Mizuho
Mizuho's checks indicate Fitbit's Charge 2 sell through remains strong with favorable reviews, despite investor concerns. The firm's analyst views the pullback in Fitbit shares as unwarranted, especially since Q3 guidance assume minimal unit sales, and expects the Charge 2 to compete well and serve as a catalyst for Holiday season into Spring 2017. Mizuho continues to believe in Fitbit's long-term opportunity to maintain dominant share with in the increasingly growing global market for wearables while pursing opportunities in the healthcare industry.
09/29/16
MZHO
09/29/16
NO CHANGE
MZHO
Fitbit shares defended at Mizuho
10/07/16
CLVD
10/07/16
NO CHANGE
CLVD
Cleveland Research is cautious on Fitbit heading into Q4 and Q1 2027
Cleveland Research is cautious on Fitbit heading into Q4 and Q1 2027 saying new product uptake is muted and is concerned about inventory levels.
09/29/16
09/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Coca-Cola (KO) downgraded to Hold from Buy at Stifel with analyst Mark Swartzberg saying that Coca-Cola's and Pepsi's organic EPS growth appears to be similar, but he believes that Pepsi is less vulnerable to foreign exchange fluctuations. 2. Fitbit (FIT) downgraded to Underweight from Sector Weight at Pacific Crest analyst Brad Erickson citing his channel checks which indicated that Charge 2, the company's flagship holiday product, is off to a slow start. 3. Discovery (DISCA) downgraded to Market Perform from Outperform at Barrington with analyst James Goss saying that Brexit and sports costs are dragging on its international results and foreign exchange tailwinds are moderating in many geographies. 4. Sonus (SONS) downgraded to Underperform from Market Perform at Cowen with analyst Paul Silverstein saying the firm's industry checks uncovered operational challenges and ongoing employee and executive churn. 5. Alcobra (ADHD) downgraded to Hold from Buy at Cantor and to Perform from Outperform at Oppenheimer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TEVA Teva
$44.56

-0.48 (-1.07%)

10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.
PG Procter & Gamble
$88.54

-0.52 (-0.58%)

10/12/16
ARGS
10/12/16
UPGRADE
Target $103
ARGS
Buy
Procter & Gamble upgraded to Buy from Hold at Argus
As previously reported, Argus analyst John Staszak upgraded Procter & Gamble to Buy from Hold after he raised his FY17 and FY18 EPS estimates based on the company's plans to accelerate R&D and advertising spending, as well as recent positive earnings surprises. Additionally, Staszak expects the company's share repurchases and consistent dividend raises to provide support for the shares, which he views as undervalued compared to the stock's three-year annual average valuation range. The analyst set a $103 price target on P&G shares.
10/12/16
ARGS
10/12/16
UPGRADE
ARGS
Buy
Procter & Gamble upgraded to Buy from Hold at Argus
08/26/16
JEFF
08/26/16
NO CHANGE
Target $75
JEFF
Hold
Jefferies cuts Edgewell Personal Care target citing Harry's rollout at Target
Jefferies analyst Kevin Grundy lowered his price target on Edgewell Personal Care (EPC) to $75 from $77 after Harry's shave club offerings launched nationwide at Target (TGT), saying his store checks revealed strong in-store execution for the roll-out. Grundy thinks soon-to-be acquired Dollar Shave Club will also to push into retail and expects other retailers, perhaps including Walmart (WMT), to follow Target's lead and offer shelf space to the "trendy" shave club brands. While saying this is also a risk to Procter & Gamble (PG), Grundy keeps his Buy rating and $98 price target on P&G shares, saying increased levels of investment in U.S. shaving are already factored in the company's guidance.
08/15/16
08/15/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Procter & Gamble (PG) upgraded to Buy from Neutral at B. Riley with analyst Linda Bolton Weiser saying she left a meeting with new Chief Executive Officer David Taylor with greater confidence in the company's improved organic sales growth. 2. Valeant (VRX) upgraded to Neutral from Underperform at Mizuho. 3. AAC Holdings (AAC) upgraded to Strong Buy from Outperform at Raymond James with analyst John Ransom ting favorable valuation, still high short interest, and good visibility on 2017 EBITDA, which is $8M above Street estimates. 4. American Eagle (AEO) upgraded to Buy from Hold at Deutsche Bank with analyst Tiffany Kanaga saying denim strength should drive upside to estimates in the second quarter while easier compares should keep the momentum going in the second half of 2016. 5. Bright Horizons (BFAM) upgraded to Overweight from Neutral at JPMorgan with analyst Andrew Steinerman saying the company is entering a period of above-average margin expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AMAT Applied Materials
$28.64

-0.74 (-2.52%)

10/12/16
PACS
10/12/16
DOWNGRADE
PACS
Sector Weight
Nanometrics, Lam Research downgraded to Sector Weight at Pacific Crest
Pacific Crest analyst Weston Twigg downgraded both Nanometrics (NANO) and Lam Research (LRCX) to Sector Weight from Overweight saying 3D NAND equipment demand is likely to peak in 2017. The analyst expects order declines and limited demand growth for semiconductor equipment names, which he sees limiting share upside. Twigg keeps Overweight ratings on Applied Materials (AMAT), MKS Instruments (MKSI) and Entegris (ENTG) for their longer term potential.
09/19/16
SBSH
09/19/16
NO CHANGE
Target $37
SBSH
Buy
Applied Materials price target raised to $37 from $32 at Citi
Citi analyst Atif Malik raised his price target for Applied Materials to $37 ahead of the company's investor day on September 21. The analyst sees multiple expansion with "spend drivers like 3D NAND, China, and OLED" remaining "in early innings," Malik tells investors in a research note. He reiterates a Buy rating on Applied Materials.
10/04/16
GSCO
10/04/16
DOWNGRADE
GSCO
Buy
Applied Materials downgraded to Buy from Conviction Buy at Goldman
Goldman analyst Toshiya Hari removed Applied Materials from the Conviction Buy List due to relative outperformance. The analyst maintains a Buy rating and $33 price target on shares given strong industry fundamentals, market share gains, opportunity in mobile display, a strong management team, and upside to Street estimates.
10/05/16
RBCM
10/05/16
NO CHANGE
RBCM
Micron report reads positively for Applied Materials, Lam, says RBC Capital
Following Micron's (MU) quarterly report and guidance, RBC Capital Amit Daryanani said he sees positive read-through from the report for Applied Materials (AMAT), Lam Research (LRCX), ASML (ASML), Western Digital (WDC) and Intel (INTC). Micron management expects capex spending of $4.8B-$5.2B for FY17, noted Daryanani, who believes continued 3D NAND spending will benefit Applied and Lam the most.
GNW Genworth
$5.14

-0.07 (-1.34%)

11/17/15
11/17/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Antero Resources (AR) initiated with a Buy at Goldman... Applied Micro Circuits (AMCC) initiated with a Buy at Drexel Hamilton... Arc Logistics (ARCX) initiated with a Buy at DA Davidson... CNO Financial (CNO) initiated with a Buy at Goldman... Capstone Turbine (CPST) initiated with a Perform at Oppenheimer... Dominion (D) initiated with an Outperform at Scotia Howard Weil... Duke Energy (DUK) initiated with a Sector Perform at Scotia Howard Weil... EQT Corporation (EQT) initiated with a Neutral at Goldman... EverBank (EVER) initiated with a Hold at Sandler O'Neill... Exelon (EXC) initiated with a Sector Perform at Scotia Howard Weil... First Data (FDC) initiated with a Neutral at BTIG... Genworth (GNW) initiated with a Neutral at Goldman... Marinus Pharmaceuticals (MRNS) initiated with a Buy at Jefferies... New Relic (NEWR) initiated with a Buy at Needham... NextEra Energy Partners (NEP) initiated with a Sector Perform at Scotia Howard Weil... NextEra Energy (NEE) initiated with an Outperform at Scotia Howard Weil... PG&E (PCG) initiated with a Neutral at Citi... Reinsurance Group (RGA) initiated with a Sell at Goldman... The Advisory Board (ABCO) initiated with an Overweight at JPMorgan... Torchmark (TMK) initiated with a Neutral at Goldman... Ubisoft Entertainment (UBSFY) initiated with a Buy at Jefferies.
10/05/16
BTIG
10/05/16
DOWNGRADE
BTIG
Neutral
Genworth downgraded to Neutral from Buy at BTIG
BTIG analyst Mark Palmer downgrading Genworth Financial to Neutral and removed its price target of $5 citing valuation.
09/22/16
WELS
09/22/16
INITIATION
WELS
Market Perform
Genworth coverage resumed with a Market Perform at Wells Fargo
09/19/16
COMP
09/19/16
DOWNGRADE
COMP
Neutral
Genworth downgraded to Neutral from Buy at Compass Point
CCL Carnival
$46.85

-0.66 (-1.39%)

10/04/16
10/04/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ACADIA (ACAD) reinstated with a Market Perform at Leerink. 2. Royal Caribbean (RCL) was initiated with an Outperform at Macquarie, while the firm initiated Carnival (CCL) and Norwegian Cruise Line (NCLH) with a Neutral. 3. Shopify (SHOP) initiated with a Buy at Goldman. 4. Dolby (DLB) assumed with a Neutral at JPMorgan. 5. United Rentals (URI) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
10/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. 3D Systems (DDD) coverage transferred with a Market Perform at FBR Capital. 2. Carnival (CCL) initiated with a Buy at HSBC. 3. GoDaddy (GDDY) initiated with a Buy at Summit Redstone. 4. Versum Materials (VSM) initiated with a Buy at Seaport Global. 5. ExOne (XONE) coverage transferred with an Outperform at FBR Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
HSBC
10/03/16
INITIATION
Target $60
HSBC
Buy
Carnival initiated with a Buy at HSBC
HSBC analyst Lena Thakkar initiated Carnival with a Buy and a $60 price target. The analyst said management has made significant strides in revenue management and cost discipline and sees signficant upside to yields. Further, Thakkar said China and fuel concerns seem overdone and expects shares to rerate on management's emphasis on 10% ROIC target.
10/04/16
MACQ
10/04/16
INITIATION
Target $55
MACQ
Neutral
Carnival initiated with a Neutral at Macquarie
Macquarie analyst Matthew Brooks initiated Carnival with a Neutral and a $55 price target given slow capacity growth and high fuel exposure.
S Sprint
$6.78

0.05 (0.74%)

09/20/16
PIPR
09/20/16
NO CHANGE
PIPR
Overweight
Piper survey shows decline in iPhone upgrade interest
Piper Jaffray analyst Gene Munster says his firm's survey of 403 U.S. iPhone owners suggests that interest in an iPhone 7 upgrade declined after the announcement of the device. The data contradicts "generally positive" initial demand indicators including from carriers including T-Mobile (TMUS) and Sprint (S), Munster tells investors in a research note. The analyst questions iPhone 7 demand into Apple's (AAPL) March and June quarters but remains confident in his thinking for flattish growth for iPhone 7 versus iPhone 6. Munster reiterates an Overweight rating on Apple.
09/15/16
FBCO
09/15/16
NO CHANGE
Target $150
FBCO
Outperform
Credit Suisse raises Apple iPhone estimates on survey, carrier comments
Credit Suisse analyst Kulbinder Garcha said that build plans noted by the firm's tech team in Japan, the firm's proprietary iPhone survey and recent announcements from Sprint (S) and T-Mobile (TMUS) all lead him to now believe that Apple's (AAPL) iPhone 7 cycle may be stronger than anticipated. Accordingly, Garcha increased his calendar year 2016 iPhone volume estimate to 215M from 208M and took his calendar year 2017 estimate up to 221M units from 217M units. Additionally, two recent surveys conducted by the firm point to a potential beneficial mix shift, as more buyers appear to be shifting toward the Plus model compared to the mix in the iPhone 6s cycle, Garcha tells investors. The analyst reiterates an Outperform rating and $150 price target on Apple shares, which closed yesterday at $111.77.
09/13/16
WELS
09/13/16
NO CHANGE
WELS
Market Perform
Apple iPhone 7 strength consistent with view, says Wells Fargo
Wells Fargo analyst Maynard Um says the iPhone 7 pre-order strength announced by T-Mobile (TMUS) and Sprint (S) is consistent with his view that "aggressive carrier promotions" should help to drive sales of the next generation phone. Um still expects Apple's multiple expansion to be limited given the "limited visibility and some concern into the March quarter." The analyst keeps a Market Perform rating on Apple shares with a $105-$120 price target range.
09/12/16
DBAB
09/12/16
DOWNGRADE
DBAB
Hold
SoftBank downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Peter Milliken downgraded Softbank (SFTBY) to Hold saying the company's rebuilding efforts should take time. The analyst expects the stock to trade largely in line with Alibaba (BABA), Sprint (S) and the yen over the next 12 months, and he feels much of the upside has already been realized in the first two.
YY YY
$53.95

-2.33 (-4.14%)

08/31/16
JPMS
08/31/16
INITIATION
Target $62
JPMS
Overweight
YY initiated with an Overweight at JPMorgan
JPMorgan analyst Alex Yao started YY with an Overweight rating and $62 price target. The company is well positioned to transition from PC broadcasting to mobile, Yao tells investors in a research note.
09/14/16
FBCO
09/14/16
INITIATION
Target $64
FBCO
Outperform
YY initiated with an Outperform at Credit Suisse
Target $64.
09/15/16
FBCO
09/15/16
INITIATION
Target $64
FBCO
Outperform
YY initiated with an Outperform at Credit Suisse
Credit Suisse analyst Zoe Zhao initiated YY with an Outperform and a $64 price target. The analyst is positive on YY due to its proven track record and recurring cash flow from PC livestreaming with optionality from mobile product evolution and adequate margin of safety on valuation.

TODAY'S FREE FLY STORIES

02:50
12/06/16
12/06
02:50
12/06/16
02:50
General news
FX Update: Most dollar pairings remained with Monday's ranges »

FX Update: Most dollar…

JUNO

Juno Therapeutics

$20.42

-0.01 (-0.05%)

23:25
12/05/16
12/05
23:25
12/05/16
23:25
Conference/Events
Juno Therapeutics to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

22:55
12/05/16
12/05
22:55
12/05/16
22:55
Conference/Events
Seattle Genetics to hold an investor reception »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

GNMSF

Genmab

$171.98

3.9767 (2.37%)

22:30
12/05/16
12/05
22:30
12/05/16
22:30
Conference/Events
Genmab to hold data review meeting »

Management discusses data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

TGTX

TG Therapeutics

$5.70

0.2 (3.64%)

22:25
12/05/16
12/05
22:25
12/05/16
22:25
Conference/Events
TG Therapeutics to hold an investor and analyst reception »

In connection with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

RHHBY

Roche

$27.67

0.47 (1.73%)

20:25
12/05/16
12/05
20:25
12/05/16
20:25
Conference/Events
Roche to hold an analyst meeting »

Analyst Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

AZO

AutoZone

$776.42

-7.32 (-0.93%)

, HDS

HD Supply

$39.75

0.67 (1.71%)

20:25
12/05/16
12/05
20:25
12/05/16
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

AZO

AutoZone

$776.42

-7.32 (-0.93%)

HDS

HD Supply

$39.75

0.67 (1.71%)

MIK

Michaels

$24.31

0.34 (1.42%)

TOL

Toll Brothers

$30.47

1.15 (3.92%)

BOBE

Bob Evans

$46.77

1.05 (2.30%)

CONN

Conn's

$11.20

0.4 (3.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 14

    Dec

  • 09

    Jan

GDDY

GoDaddy

$34.74

1.45 (4.36%)

20:14
12/05/16
12/05
20:14
12/05/16
20:14
Hot Stocks
GoDaddy acquires WP Curve »

WP Curve announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$74.99

0.9 (1.21%)

20:10
12/05/16
12/05
20:10
12/05/16
20:10
Earnings
Belden sees FY17 adjusted EPS $5.00-$5.25, consensus $5.23 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SGMO

Sangamo

19:39
12/05/16
12/05
19:39
12/05/16
19:39
Hot Stocks
Sangamo reports preclinical, manufacturing data on SB-525, says IND on track »

Sangamo BioSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

, BMY

Bristol-Myers

$55.55

-0.41 (-0.73%)

19:38
12/05/16
12/05
19:38
12/05/16
19:38
Hot Stocks
Seattle Genetics, Bristol-Myers: Data supports ADCETRIS, Opdivo combo »

Seattle Genetics (SGEN)…

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

BMY

Bristol-Myers

$55.55

-0.41 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

LGIH

LGI Homes

$32.34

0.45 (1.41%)

19:36
12/05/16
12/05
19:36
12/05/16
19:36
Hot Stocks
LGI Homes reports November home closings up 28.9% y/y »

LGI Homes announced 321…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$116.56

-1.07 (-0.91%)

19:36
12/05/16
12/05
19:36
12/05/16
19:36
Hot Stocks
Celgene reports analysis of three CC-486 studies »

Celgene announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

BLUE

bluebird bio

$72.15

2.4 (3.44%)

19:35
12/05/16
12/05
19:35
12/05/16
19:35
Hot Stocks
bluebird bio provides updates on HSC gene therapy programs »

bluebird bio provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$49.88

-7.09 (-12.45%)

19:33
12/05/16
12/05
19:33
12/05/16
19:33
Hot Stocks
Agios 'encouraged' by durable clinical activity of AG-120 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$60.25

-0.88 (-1.44%)

19:31
12/05/16
12/05
19:31
12/05/16
19:31
Hot Stocks
Merck: KEYNOTE-087 trial data shows oORR of 69%, CRR of 22.4% »

Merck announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 08

    Mar

TWX

Time Warner

$93.34

-0.46 (-0.49%)

, T

AT&T

$38.63

0.02 (0.05%)

19:29
12/05/16
12/05
19:29
12/05/16
19:29
Periodicals
Time Warner 'struggling to expand' HBO Now, NY Post says »

Time Warner (TWX) is…

TWX

Time Warner

$93.34

-0.46 (-0.49%)

T

AT&T

$38.63

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

BP

BP

, REPYY

Repsol

$13.88

0.25 (1.83%)

19:18
12/05/16
12/05
19:18
12/05/16
19:18
Periodicals
BP acquires Repsol stake in Indonesia LNG plant, Reuters says »

BP (BP) has purchased…

BP

BP

REPYY

Repsol

$13.88

0.25 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOSUF

Fosun

19:12
12/05/16
12/05
19:12
12/05/16
19:12
Hot Stocks
Liberty Mutual to acquire Fosun subsidiary Ironshore for roughly $3B »

Liberty Mutual Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$49.75

-0.06 (-0.12%)

, YHOO

Yahoo

$40.20

0.13 (0.32%)

18:54
12/05/16
12/05
18:54
12/05/16
18:54
Periodicals
AOL CEO 'cautiously optimistic' Verizon-Yahoo deal will go through, WSJ says »

AOL CEO Tim Armstrong…

VZ

Verizon

$49.75

-0.06 (-0.12%)

YHOO

Yahoo

$40.20

0.13 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 24

    Jan

TUWOY

Tullow Oil

$2.06

0.109 (5.58%)

18:46
12/05/16
12/05
18:46
12/05/16
18:46
Downgrade
Tullow Oil rating change  »

Tullow Oil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBNK

Guaranty Bancorp

$22.15

0.75 (3.50%)

18:43
12/05/16
12/05
18:43
12/05/16
18:43
Hot Stocks
Breaking Hot Stocks news story on Guaranty Bancorp »

Castle Creek raises stake…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATKR

Atkore

$20.48

-0.18 (-0.87%)

18:41
12/05/16
12/05
18:41
12/05/16
18:41
Syndicate
Atkore files to sell 8M shares of common stock for holders »

The offering is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$107.42

-0.8 (-0.74%)

18:38
12/05/16
12/05
18:38
12/05/16
18:38
Hot Stocks
United Technologies CEO: No quid pro quo on taxes in Carrier deal with Trump »

Says Carrier agreement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPDN

Professional Diversity Network

$9.75

-0.01 (-0.10%)

18:37
12/05/16
12/05
18:37
12/05/16
18:37
Hot Stocks
Breaking Hot Stocks news story on Professional Diversity Network »

North Star cuts passive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.